As Vice President and Associate Chief Medical Officer at BioReference Laboratories, one of the largest clinical labs in the United States, Dr Tamera Paczos oversaw the addition of p16/Ki-67 dual staining assays to the lab’s assay portfolio. In the US, these assays are used in triage to further risk stratify women who have come for follow-up with an initial high risk HPV positive result or have discrepant co-testing results (HPV positive, pap cytology negative).

In this talk at the 21st International Congress of Cytology (ICC) held jointly with the American Society of Cytopathology’s (ASC) 70th Annual Scientific Meeting , Dr Paczos describes rigorous verification studies they undertook to implement this test offering in her lab, a process that involved using a mix of samples from different lesion grades and benchmarking them against values as provided by the College of American Pathologists (CAP). She also shares her experience and real-life case studies of how p16/Ki-67 dual stained slides are interpreted, along with how the team handles the interpretation of challenging samples.